Home/Filings/4/0000905718-19-000763
4//SEC Filing

Zarrabian Saiid 4

Accession 0000905718-19-000763

CIK 0001498382other

Filed

Sep 8, 8:00 PM ET

Accepted

Sep 9, 4:39 PM ET

Size

7.9 KB

Accession

0000905718-19-000763

Insider Transaction Report

Form 4
Period: 2019-09-05
Zarrabian Saiid
DirectorInterim CEO
Transactions
  • Award

    Options (Right to Buy)

    2019-09-05+241,438241,438 total
    Exercise: $0.61Exp: 2029-09-05Common Stock (241,438 underlying)
  • Award

    Options (Right to Buy)

    2019-09-05+216,212216,212 total
    Exercise: $0.61Exp: 2029-09-05Common Stock (216,212 underlying)
Footnotes (2)
  • [F1]Subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the next annual meeting, 1/6th of the options vest on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020.
  • [F2]1/6th of the options vest on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020.

Issuer

DelMar Pharmaceuticals, Inc.

CIK 0001498382

Entity typeother

Related Parties

1
  • filerCIK 0001495521

Filing Metadata

Form type
4
Filed
Sep 8, 8:00 PM ET
Accepted
Sep 9, 4:39 PM ET
Size
7.9 KB